Search
News
AMN Healthcare Q2 2026 Earnings: Staffing Growth Lifts Adjusted EBITDA 26%
AMN Healthcare’s Q2 2026 revenue rose 2% year over year to $673.2 million, while GAAP diluted EPS improved to $0.53 from a $3.02 loss per share. Adjusted EBITDA increased 26% to $73.4 million and gross margin expanded 80 basis points to 30.6%, supported partly by labor-disruption reserve releases and billing true-ups. Operating cash flow was negative $189.9 million as client deposits were returned. Nurse and Allied revenue grew 11%, while Technology and Workforce fell 15%. For Q3, AMN guided to $640 million-$655 million of revenue and a 6.5%-7.0% adjusted EBITDA margin.
TradingKey
Thu, Aug 6
Groupon Q2 2026 Earnings: Revenue Slips 1% as Continuing Operations Turn to a Loss
Groupon’s Q2 2026 revenue and billings each declined 1% year over year, while the company reported a $1.5 million loss from continuing operations versus $20.6 million of income a year earlier. Adjusted EBITDA was $14.8 million, and free cash flow remained positive at $15.0 million despite falling from $25.2 million. North America Local softness contrasted with reported International Local growth, while active customers rose 2% but unit sales fell 7%. Groupon guided to 3%-5% full-year revenue and billings growth and at least $60 million of free cash flow.TradingKey
Thu, Aug 6
CytomX Q2 2026 earnings: Collaboration revenue decline widens loss
CytomX Therapeutics’ Q2 2026 revenue fell about 92% year over year to $1.4 million, while diluted loss per share widened to $0.09 from $0.00 after rounding. Operating expenses rose to $25.2 million as Varseta-M manufacturing and personnel costs increased R&D spending. CytomX ended June with $330.3 million in cash, cash equivalents and investments, excluding a $37.0 million Regeneron payment received in July, and expects its funding to last at least into the second half of 2028.
TradingKey
Thu, Aug 6
Kingstone Q2 2026 earnings: Record profit despite a higher underlying combined ratio
Kingstone’s Q2 2026 net premiums earned rose 30.8% to $60.5 million, diluted EPS increased 34.6% to $1.05, and net income reached a company-record $15.5 million. The GAAP net combined ratio improved 1.3 points to 70.2%, helped by favorable prior-year reserve development and a negative catastrophe loss ratio, while the underlying combined ratio worsened 2.3 points to 73.7%. The insurer reaffirmed full-year 2026 guidance, including diluted EPS of $2.20 to $2.90 and a net combined ratio of 81% to 86%. Direct premiums written grew 18.7%.
TradingKey
Thu, Aug 6
Clarus Q2 2026 earnings: Tariff refund drives margin expansion
Clarus Corporation’s Q2 2026 revenue rose 1.6% to $56.2 million, while diluted EPS swung to $0.12 from a $0.22 loss. Gross margin expanded to 48.9%, with a $6.1 million IEEPA tariff refund contributing 10.9 percentage points, and adjusted EBITDA reached $7.6 million versus a $4.4 million loss a year earlier. Outdoor sales grew 8.5%, offsetting an 11.9% decline in Adventure. Clarus reaffirmed full-year sales guidance of $245 million to $255 million and now expects adjusted EBITDA of approximately $12 million to $13 million.
TradingKey
Thu, Aug 6
Microchip Q1 FY2027 earnings: Revenue recovery lifts margins and cash flow
Microchip Technology’s Q1 fiscal 2027 net sales rose 38.0% year over year to $1.485 billion, while GAAP diluted EPS improved to $0.37 from a $0.09 loss. GAAP operating margin expanded to 22.7%, and free cash flow nearly doubled to $497.6 million as demand and factory utilization improved. For Q2, Microchip expects net sales of $1.589 billion to $1.618 billion and further margin expansion, supported by continued operating leverage and inventory normalization.
TradingKey
Thu, Aug 6
HCI Group Q2 2026 Earnings: Pretax Income Outpaces Revenue Growth
HCI Group’s Q2 2026 total revenue rose 11.1% year over year to $246.7 million, while diluted EPS increased to $5.60 from $5.18. Pretax income climbed 17.6% to $111.0 million as net premiums earned, investment income and Exzeo-related other revenue increased. Gross premiums earned grew 6% on higher policy counts, although the gross loss ratio rose to 22.2% and personnel costs increased. Lower ceded premiums following the June 1 reinsurance renewal and lower interest expense supported profitability, while Tailrow accounted for much of the carrier-level premium growth.
TradingKey
Thu, Aug 6
Scripps Q2 2026 earnings: $1.1 billion impairment magnifies operating pressure
Scripps reported Q2 2026 revenue of $490.4 million, down 9.2% year over year, and a diluted loss of $12.68 per share versus $0.59 a year earlier. A $1.14 billion non-cash impairment drove most of the GAAP loss, while adjusted EBITDA fell to $55.2 million from $88.9 million. Local Media profit held flat as lower costs and record political advertising helped offset retransmission blackouts, but Scripps Networks revenue declined 16.5% and segment profit fell 54.4%. Q3 guidance calls for about 20% Local Media revenue growth but continued Networks pressure.
TradingKey
Thu, Aug 6
Alta Q2 2026 earnings: Margin gains keep adjusted EBITDA flat
Alta Equipment Group’s Q2 2026 revenue fell 1.2% to $475.5 million, while diluted loss per share widened to $0.25 from $0.21. Gross profit rose 1.6% and adjusted EBITDA held nearly flat at $48.6 million as equipment and service margins improved despite lower sales. First-half operating cash flow turned positive at $26.1 million, supported by working-capital and fleet actions, while adjusted net debt remained elevated. Management tightened full-year adjusted EBITDA guidance to $167.5 million-$177.5 million and cited improving bookings and easing tariff disruption.
TradingKey
Thu, Aug 6
Globus Medical Q2 2026 Earnings: Margin Expansion Lifts Adjusted EPS
Globus Medical (GMED) reported Q2 2026 net sales of $789.6 million, up 5.9% year over year. GAAP diluted EPS fell 26.2% to $1.10 because the prior-year quarter included a $110.5 million Nevro bargain-purchase gain, while non-GAAP diluted EPS rose 55.8% to $1.34. Adjusted EBITDA margin expanded to 35.4%, and quarterly free cash flow increased to $176.6 million. Musculoskeletal Solutions grew while Enabling Technologies declined. The company reaffirmed full-year revenue guidance and raised its non-GAAP EPS range to $4.95-$5.05.
TradingKey
Thu, Aug 6
Seneca Foods Fiscal Q1 2027 Earnings: Sales Rise 36% as Reported Gross Margin Narrows
Seneca Foods’ fiscal Q1 2027 net sales rose 36.2% to $405.2 million, while diluted EPS increased to $2.85 from $2.14 and net earnings reached $19.5 million. Growth was driven by the Green Giant Frozen acquisition, private-label momentum, and Co-pack timing. Reported gross margin fell to 11.8% from 14.1%, but management said FIFO gross margin expanded 100 basis points as high-cost inventory cleared. FIFO EBITDA increased to $38.0 million from $25.2 million.TradingKey
Thu, Aug 6
X4 Pharmaceuticals Q2 2026 Earnings: License Revenue Helps Narrow the Net Loss
X4 Pharmaceuticals’ Q2 2026 revenue rose to $8.8 million from $2.0 million, supported primarily by $6.4 million of license and other revenue, while U.S. XOLREMDI net product sales reached $2.4 million. Net loss narrowed to $16.2 million from $25.7 million, and diluted loss per share improved to $0.13 from $3.47, although the share count was substantially higher. X4 ended June with $208.0 million in cash and marketable securities and said its funding should extend into 2029.
TradingKey
Thu, Aug 6
ESCO Fiscal Q3 2026 Earnings: Revenue Rises 14% as Backlog Hits a Record
ESCO Technologies’ fiscal Q3 2026 revenue rose 14% to $339.0 million, supported by 8% organic growth and a $23 million contribution from Maritime. GAAP diluted EPS from continuing operations increased 31% to $1.26, while adjusted EPS climbed 38% to $2.20 as adjusted EBIT margin expanded 90 basis points. Aerospace & Defense led segment growth, and quarterly orders of $409.5 million lifted backlog to a record $1.54 billion. ESCO also raised FY2026 adjusted EPS guidance to $8.30-$8.40 and expects the Megger acquisition to close in fiscal Q1 2027.
TradingKey
Thu, Aug 6
Valhi Q2 2026 Earnings: Chemicals Drive the Profit Increase
Valhi’s Q2 2026 net sales rose approximately 12% year over year to $606.1 million, while basic and diluted EPS increased to $0.78 from $0.03. Reported total operating income climbed to $67.7 million from $35.5 million, led by Chemicals, where sales reached $558.1 million and operating income rose to $40.4 million. Higher TiO2 volumes, lower production costs and prior cost reductions offset weaker pricing and adverse currency effects on profit. Key issues include TiO2 pricing, foreign exchange and higher interest expense.
TradingKey
Thu, Aug 6
PSI Q2 2026 earnings: Shipment timing weighs on sales as debt falls $30.8 million
Power Solutions International (PSI) Q2 2026 net sales fell 21% year over year to $152.5 million, while diluted EPS declined to $0.73 from $2.22. Gross margin was 27.1%, down 110 basis points year over year but up about 420 basis points sequentially as Wisconsin operating improvements began to offset ramp-up costs. Shipment timing for data center-related Power Systems orders and weaker oil and gas demand weighed on revenue. Operating cash flow reached $56.6 million, helping PSI reduce total debt by about $30.8 million during the quarter.
TradingKey
Thu, Aug 6
Trevi Q2 2026 Earnings: Higher Trial Spending Widens the Net Loss
Trevi Therapeutics’ Q2 2026 earnings reflected a step-up in clinical development spending as the company launched the Phase 3 OCEAN-1 and Phase 2b LAKE trials. R&D expense rose to $15.2 million from $9.4 million, contributing to a wider net loss of $17.8 million, or $0.11 per share. Cash, cash equivalents and marketable securities totaled $318.9 million after an April equity offering generated approximately $162.3 million in net proceeds. Trevi expects this capital to extend its runway into 2030.
TradingKey
Thu, Aug 6
CVRx Q2 2026 Earnings: U.S. Growth Continues as Execution Pressures the Outlook
CVRx’s Q2 2026 revenue rose 16% year over year to $15.7 million, led by 21% growth in the U.S., while gross margin improved to 87% from 84%. The company reported a $14.0 million net loss, or $0.53 per share, compared with a $14.7 million loss, or $0.57 per share, a year earlier. Management updated full-year revenue guidance to $58.0 million-$60.0 million as sales capacity, productivity issues, and a prolonged challenge with a major payer tempered the outlook despite reimbursement progress.
TradingKey
Thu, Aug 6
Apyx Medical Q2 2026 earnings: Surgical Aesthetics growth narrows losses
Apyx Medical’s Q2 2026 revenue increased 22.1% to $13.9 million, led by 28.1% growth in Surgical Aesthetics. Net loss attributable to stockholders narrowed to $3.2 million, or $0.07 per diluted share, and the adjusted EBITDA loss improved to $0.7 million. Gross margin expanded 160 basis points to 63.9% as business mix improved, although tariffs remained a partial offset. Operating cash use rose to $3.5 million because of working-capital changes. Apyx reaffirmed FY2026 revenue guidance of $59 million to $60 million, with AYON expected to support second-half growth.
TradingKey
Thu, Aug 6
Sprout Social Q2 2026 Earnings: 11% Revenue Growth and Wider Margins
Sprout Social’s Q2 2026 revenue rose 11% year over year to $123.8 million, while non-GAAP diluted EPS increased to $0.26 from $0.18. The GAAP operating loss narrowed to $2.7 million, and non-GAAP operating income reached $16.0 million as operating expenses remained roughly flat. Free cash flow rose to $8.3 million, RPO increased 16% to $400.8 million, and the company raised its Q4 2026 exit non-GAAP operating-margin outlook to approximately 17%.
TradingKey
Thu, Aug 6
Oculis Q2 2026 Results: Finance Gains Narrow the Net Loss Despite Higher Costs
Oculis reported Q2 2026 grant income of CHF 0.3 million and a diluted loss per share of CHF 0.16, versus CHF 0.49 a year earlier. The quarterly net loss narrowed to CHF 10.0 million even as the operating loss widened to CHF 23.6 million, mainly because warrant remeasurement and foreign-exchange gains lifted the finance result. Cash and short-term investments totaled CHF 228.3 million, supporting runway into the second half of 2029, while Privosegtor and Licaminlimab registrational programs advanced. Oculis also dropped plans for an OCS-01 DME filing.TradingKey
Thu, Aug 6
Featured Tools
Top News
Meta Q3 Net Profit Surges 264% YoY, Raises Full-Year Capex Slightly; Shares Briefly Rise Over 4% After Hours
US Stocks Close: Nasdaq Drops 2.6%, SOX Falls Over 6%; Jensen Huang's Remarks on Capital Shortage Spark Financing Concerns, Meta Drops 7% After Earnings
Bloom Energy Q3 Revenue Up 138% YoY, EPS Swings to Profit, But Shares Tumble 7% After Hours
US Stocks Close: Nasdaq Gains Over 1%, Philadelphia Semiconductor Index Rises Nearly 2%; Tech Stocks Strengthen, SpaceX Gains Nearly 8% Post-Earnings
Memory Stocks Fall Over 4% as Micron Drops Below $900, Risking Another 16% Fall to Retest Lows
